MOLECULAR PHARMACEUTICS, published by the American Chemical Society, stands as a pivotal journal within the fields of Drug Discovery, Molecular Medicine, and Pharmaceutical Science, as evidenced by its impressive rankings in various categories, including Q1 in Drug Discovery and Pharmaceutical Science. With an ISSN of 1543-8384 and an E-ISSN of 1543-8392, this journal has been at the forefront of research since its inception in 2004 and continues to foster innovation and collaboration among researchers, professionals, and students well into 2024. The journal is noted for its significant impact, having achieved a Scopus ranking of #31 in Pharmaceutical Science and #36 in Drug Discovery, placing it in the top percentiles of the respective fields. While it currently does not offer Open Access, MOLECULAR PHARMACEUTICS remains an essential resource for advancing the understanding of molecular mechanisms in drug development and therapeutic strategies, ensuring that cutting-edge findings reach a wide audience and contribute to the progression of pharmaceutical sciences.

European Journal of Pharmaceutics and Biopharmaceutics is a leading academic journal published by Elsevier, dedicated to advancing the field of pharmaceutical sciences through high-quality research. Established in 1991, this multidisciplinary journal offers a platform for the dissemination of innovative findings in pharmaceutics and biopharmaceutics, covering crucial aspects such as drug formulation, delivery systems, and the interface of pharmaceutical formulation with biological systems. The journal is well-regarded for its impact, earning a Q1 status in Pharmaceutical Science and consistent Q2 rankings in both Biotechnology and Medicine (Miscellaneous) categories in 2023, thereby highlighting its significance in the scientific community. With an impressive Scopus ranking of 26th percentile in Pharmaceutical Science and 60th percentile in Biotechnology, it positions itself firmly at the forefront of research, supporting researchers, professionals, and students in their quest to address complex health challenges. While the journal does not offer an open-access option, it facilitates a rigorous peer-review process, ensuring that published articles meet the highest standards of scientific integrity. For those looking to make meaningful contributions to the field, the European Journal of Pharmaceutics and Biopharmaceutics serves as an essential resource and reference point.

The European Journal of Pharmaceutical Sciences is a prestigious academic journal dedicated to advancing the field of pharmaceutical science. Published by Elsevier, the journal boasts an impressive impact factor and is categorized in the Q1 quartile for pharmaceutical science as of 2023, signifying its influence and reputation within the academic community. With a Scopus ranking of #20 out of 183 in the fields of pharmacology, toxicology, and pharmaceutics, the journal provides a vital platform for researchers and practitioners to disseminate innovative studies and groundbreaking research that push the boundaries of drug development and delivery. Based in the Netherlands and operating since 1993, the journal seeks to cover a broad scope of topics related to pharmaceutical sciences, encouraging rigorous evaluations and discussions that enhance the understanding and application of this critical field. The absence of open access underscores the commitment to maintaining high scholarly standards, while still offering avenues for libraries and institutions to provide access to cutting-edge research. As the journal converges towards its 2024 milestones, it continuously aims to foster a vibrant exchange of knowledge among its diverse readership, comprising committed researchers, professionals, and students.

Journal of Pharmaceutical Investigation, published by SPRINGERNATURE, is a leading academic resource in the field of pharmaceutical sciences, offering critical insights and innovative research findings. With an impact factor that underscores its significance, this journal ranks in the Q1 category for both Pharmacology and Pharmaceutical Science as of 2023, showcasing its high-quality publications and rigorous peer-review processes. Operating from the Netherlands, the journal spans from 2012 to 2024, offering a rich archive of interdisciplinary research contributions that advance knowledge in pharmacology, toxicology, and pharmaceutics. It holds impressive Scopus rankings, placing it among the top-tier journals in its categories, which enhances its appeal to researchers, professionals, and students aiming to publish their work or stay up-to-date with the latest advancements in the pharmaceutical field. Engaging with the Journal of Pharmaceutical Investigation not only enriches your understanding but also connects you with a community dedicated to advancing healthcare and therapeutic innovations.

Current Drug Delivery, published by Bentham Science Publishers Ltd, serves as a vital platform for advancing the field of pharmaceutical sciences. With an ISSN of 1567-2018 and an E-ISSN of 1875-5704, this esteemed journal focuses on all aspects of drug delivery systems, encompassing innovative research and developments that aim to improve therapeutics and patient outcomes. Operating from the United Arab Emirates, it has an impressive standing reflected in its 2023 Q2 ranking in Pharmaceutical Sciences and a notable position within the 62nd percentile in Scopus’s Pharmacology, Toxicology, and Pharmaceutics category. The journal not only acts as an essential resource for researchers and professionals but it also encourages the dissemination of knowledge among students and budding scientists. With the latest articles and reviews converging from 2004 to 2024, Current Drug Delivery remains committed to offering high-quality content that enhances understanding and sparks innovation in drug delivery mechanisms.

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.

Asian Journal of Pharmaceutical Research and Health Care, published by Wolters Kluwer Medknow Publications, serves as a vital platform for disseminating cutting-edge research in the fields of pharmacology, toxicology, and healthcare. With an ISSN of 2250-1444 and an E-ISSN of 2250-1460, this journal aims to provide valuable insights and advancements in pharmaceutical sciences, targeting researchers, practitioners, and students dedicated to improving health outcomes. Although its coverage in Scopus was discontinued in 2016, the journal maintains importance within the academic community by fostering discourse and sharing knowledge on emerging topics. Despite its challenges reflected in the low Scopus ranking within its category, the Asian Journal of Pharmaceutical Research and Health Care remains committed to enhancing access to critical research and publishing high-quality work that bridges the gap between theory and practice in health care. Researchers and professionals engaged in the pharmaceutical field are encouraged to contribute and leverage this journal as a means to advance their work and elevate healthcare standards in Asia and beyond.

Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.